Bullish
This article provides a comprehensive list of SEC filings and company documents for Bristol-Myers Squibb Company's Contingent Value Rights. It details...
Bullish
Beeline Medicines has raised an additional $126.3 million in its Series A extension, bringing its total funding to $426.3 million. This significant in...
Bristol Myers Squibb (BMY) recently outperformed the S&P 500, with its stock up 1.81% at $58.56. The company is set to release its earnings on July 30...
Neutral
This article displays the forward price-to-earnings ratio for Bristol-Myers Squibb Company (NYSE: BMY). It lists the stock on the New York Stock Excha...
Bristol Myers Squibb (BMY) is currently deemed 13% undervalued by Simply Wall St, with a fair value of $62.96 compared to its recent close of $54.70. ...
Bristol-Myers Squibb (NYSE: BMY) has declared a quarterly dividend of $0.63 per share. This dividend will be payable on August 3 to shareholders of re...
Bristol Myers Squibb (BMY) has announced a dividend. This news is a brief update from Reuters, indicating a financial action by the company.
Bullish
Bristol Myers Squibb announced that its Board of Directors has declared a quarterly dividend of $0.63 per share. The dividend will be payable on Augus...
Bullish
Bristol Myers Squibb significantly reduced its request for proposal (RFP) timeline from nine months to under 30 days by implementing an AI-driven proc...
Bullish
Bristol Myers Squibb (BMS) has appointed Mayada Al-Ahmad as the new General Manager for Saudi Arabia and Gulf Countries, including the UAE, Kuwait, Qa...
Bullish
Bristol Myers Squibb (BMY) offers a 4.39% dividend yield, backed by 94 years of payments and a lean 41% payout ratio, making it an attractive income s...
Bullish
Victory Capital Management Inc. significantly increased its stake in Bristol Myers Squibb (BMY) by over 102% in Q4, acquiring an additional 4.14 milli...
Neutral
Vontobel Holding Ltd. significantly reduced its stake in Bristol Myers Squibb, selling 248,546 shares in the fourth quarter, though still retaining a ...
Neutral
Representative Mike Kelly of Pennsylvania sold Bristol-Myers Squibb (NYSE: BMY) stock worth between $16,002 and $65,000, with the transaction occurrin...
Neutral
Takeda Pharmaceutical announced that its AI-designed psoriasis pill, zasocitinib, significantly outperformed Bristol Myers Squibb's Sotyktu in a head-...
Bearish
Takeda's AI-designed oral psoriasis drug, zasocitinib, significantly outperformed Bristol Myers Squibb’s Sotyktu in a Phase 3 study, achieving complet...
Neutral
Takeda Pharmaceutical announced that its experimental AI-developed psoriasis pill, zasocitinib, demonstrated superior efficacy compared to Bristol Mye...
Neutral
Takeda's experimental autoimmune drug, zasocitinib, outperformed Bristol Myers Squibb's Sotyktu in a head-to-head study for psoriasis, demonstrating s...
Bristol-Myers Squibb (BMY) has received positive news regarding its pipeline, including a Priority Review for Camzyos in adolescent obstructive hypert...
Bullish
Motley Fool Asset Management LLC increased its stake in Bristol Myers Squibb Company by 30.4% in the fourth quarter, acquiring an additional 50,403 sh...